INTRODUCTION AND OBJECTIVES:
We present here oncological outcome for patients with International Society of Urological Pathology (ISUP) Grade 5 prostate cancer (PC) who underwent primary treatment with robotic assisted laparoscopic radical prostatectomy (RALP).
METHODS: Using a prospectively collected institutional registry, we identified patients with clinically organ confined and locally advanced (cT1-T3N0M0) ISUP Grade 5 PC who underwent RALP with bilateral pelvic lymphadenectomy as primary treatment between 2005 and 2013.
RESULTS: We included 106 patients with median age of 65 years . The majority of patients had clinically organconfined disease (90%). Following surgery, 71 patients (67%) were upstaged to pT3 and 40 patients (38%) were downgraded to Gleason score 8 or 7. With median follow-up of 63.5 months (IQR 34-85), 50 patients (48%) had biochemical failure: 24 patients (23%) had PSA persistence and 26 patients (24%) had biochemical recurrence (BCR). Adjuvant and salvage RT were administered to 12 (11%) and 34 (32%) patients, respectively; adjuvant and salvage ADT were given to two (2%) and 31 (29%) patients, respectively; 9 patients (8%) received subsequent therapies. Eleven patients (10%) had systemic failure and 10 patients (9.5%) died: 3 (3%) from prostate cancer and 7 (7%) from other causes. Using Kaplan-Meier estimate, the 5-year overall, disease specific, metastasis-free and disease-free survivals are 91%, 96%, 88%, and 59% respectively. Using univariate analysis, pre-operative PSA, number of cores involved with ISUP grade 5 PC on biopsy, percentage of positive cores on biopsy, and pathological T stage were all correlated with both biochemical and systemic failure.
CONCLUSIONS: The disease volume on pre-operative biopsy and specifically the amount of Gleason 5 pattern predicted both biochemical and systemic failure. RALP in ISUP grade 5 PC is a viable treatment option in the multimodality management of PC, it affords local control and might improve long-term oncologic outcomes. METHODS: A single Tertiary Referral academic institution cohort of 2886 consecutive patients who underwent open or laparoscopic RP and pelvic lymph node dissection (PLND) for PCa between November 1995 and April 2015 was evaluated. Patients referred to neoadjuvant therapy and those lacking clinical, pathologic, and followup data were excluded. The final population consisted of 615 patients with at least one AF: preoperative PSA ¼20 ng/mL, pathologic Gleason score ¼8 and no organ-confined disease at final pathology (seminal vesicle involvement, and/or positive surgical margins, and/or lymph node invasion). Kaplan-Meier analyses were used to assess cancerspecific mortality (CSM)-free survival rates by stratifying patients into 3 risk categories according to the number of AFs (namely, 1, 2, and 3 AFs). Multivariable competing risk Cox regression analyses were used to assess CSM. The study was performed in line with the Helsinki Declaration.
RESULTS: Overall, 420 (68.2%) men had 1 AF, 156 (25.3%) had 2 AFs and 39 had 3 AFs (6.3%): among these different risk categories, significant differences in terms of preoperative and pathologic tumor characteristics, adjuvant therapies and biochemical recurrence were found (all p¼0.01); overall, 44 (7.1%) of 615 patients died of PCa. Men with 1 AF had higher CSM-free survival estimates compared to those with 2 and 3 AFs (92.8% vs. 84.2% vs. 27.7% at 10 years' follow-up, p<0.001 - Figure) . At multivariate competing risk Cox regression analyses, the presence of 3 AFs (hazard ratio [HR]: 2.59), postoperative treatment status, namely adjuvant androgen deprivation therapy (aADT) alone/aADT plus adjuvant radiotherapy (aRT; HR: 2.44) and time to BCR (HR: 0.96), were all independent predictors of CSM (all p<0.04). In the subgroup of individuals referred to aADT alone, men with 2 AFs (HR: 3.11) and 3 AFs (HR: 5.14) had a higher risk of cancerrelated death compared to those with 1 AF (all P¼0.04).
CONCLUSIONS: The risk group stratification according to the number of AFs could help physicians to accurately predict oncologic outcomes selecting PCa patients for the most appropriate postoperative strategies. METHODS: We included 111 and 180 patients with intermediate and high risk prostate cancer undergoing radical prostatectomy with standard frozen section and a new approach between 2014 and 2016. Clinical, pathological and perioperative parameters were obtained retrospectively. The Tue-safe approach included assessment of the whole circumference separated in the apical and basal section and both sided layer corresponding to the neurovascular bundle. In the standard frozen section group number and region of specimen was decided individually on behalf of the surgeon. Pathologic outcome was compared in the whole cohort and in the subgroups of intermediate and high risk.
Source of
RESULTS: The two groups did not differ in terms of Age, PSA value, D Amico-Risk-Score, Gleason-score. In the whole cohort there was no significant difference, but a clear trend in reduced postoperative surgical margin between the Tue-Safe-technique and standard frozen section (20.72% and 29.83%; p¼0.0561). In the high risk group we could show a trend towards reduction in PSM with Tue-Safe compared to standard frozen section (26.09% and 39.39%; p¼0.1032) In the intermediate risk group we found a significant reduction in PSM at the base of the prostate in the Tue-Safe group compared to standard frozen section (1.54% and 8.70%; p¼0.0335).
CONCLUSIONS: Due to the Tue-Safe technique the rate of PSM showed a trend towards a reduction, thereby lowering the rate of potential subsequent therapies like adjuvant radiotherapy. This trend was also present in the high risk cohort. This shows that RPx is a valid option in the treatment of high-risk patients and is thereby able to avoid the concomitant use of ADT which is required if radiotherapy is chosen as a therapy in this high-risk population. In addition, within a concept of multimodal therapy of high-risk patients, a negative residual margin may decrease the rate of bi or trimodal treatments in this patient cohort. Further investigation in a bigger cohort is needed to prove the benefit of the Tue-Safe technique. RESULTS: 2383 men were investigated. Approx. 45% had locally advanced disease and 44% had PSM. Significantly higher PSM rates were noted in men with suspicious digital-rectal examination (DRE), pT>2, GS>7 and preop.-PSA>10ng/ml. PSM-rate was also significantly influenced by the surgeon and BMI>25. PT>2, suspicious DRE and preop. PSA>10ng/ml were associated with Gleason-pattern >3 at PSM. Gleason-pattern at PSM did not influence postop. PSA. PSM significantly influenced biochemical recurrence (BCR). Men with PSM had significantly higher PSA at 3, 6, 12, 24, 36, 48 and 60 months. The chance of BCR at 3, 6, 12 and 24 months significantly correlated to preop. PSA. Multivariate analyses revealed significantly higher PSMs only in pT>2 (p<0.001), GS>7(p¼0.001), preop. PSA>10ng/ ml(p<0.001), BMI>25(p¼0.02) and suspicious DRE(p¼0.05). Preop. PSA significantly correlated to pT>2 (p<0.001), GS>7(p¼0.001), pN+(p¼0.001), PSM(p<0.001), and BCR(p¼0.05) in the multivariate analysis. 24% received RT; significantly more men with PSM(p<0.001) or GS>7(p<0.001) received RT. pT-stage, GS, PSM and pattern at PSM ( a p<0.001) influenced RT-regime significantly. BCR at 12(p<0.001) months was significantly lower after ART; there was no significant correlation between RT-regime and BCR afterwards. RDE(p¼0.02), ECOG-Score(p¼0.02), pT-stage(p<0.001), GS (p<0.001), PSM (p¼0.01) significantly affected CSS. RFS was significantly influenced by pT-stage(p<0.001), PSM(p¼0.001), GS (p¼0.002), preop. PSA(p<0.001) and suspicious DRE(p¼0.001) in the multivariate investigation CONCLUSIONS: Aggressive tumour specific characteristics like preop. PSA>10, pT>2 and GS>7 and BMI significantly increased risk for PSM. PSM also considerably influenced BCR. These results underline the importance of early cancer detection enabling prompt therapy. Techniques to reduce PSM-rate especially in advanced prostate cancer should be concurrently explored. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e851
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